Select Page

Clinical Overview

Clinical Overview

Eleview® is a submucosal injection agent that offers reliable performance for GI endoscopic procedures, resulting in easy and safe resections.1

Efficacy of Eleview® submucosal injection agent

Efficacy

Explore how Eleview® creates reliable submucosal lift that lasts for up to 45 minutes, outperforms saline, and maintains cushions without releasing liquid after resections.2

Go to Efficacy
Clinical results for Eleview® injection agent

Clinical Results

Learn about the procedural efficiency of Eleview®. In clinical use, Eleview® trended toward less time to resect a lesion, less overall procedure time, and resulted in fewer and larger pieces.2,3

Go to Clinical Results
Polyp after injection with Eleview® submucosal injection agent

Study Design

View the study design for a randomized, double-blind trial comparing the effectiveness and safety of Eleview® with normal saline mixed with methylene blue.

Go to Study Design
Components of Eleview® injection agent

Composition

Explore the components that create long-lasting lift, enhance visualization of lesion margins, and help contribute to a lowered risk of perforation.1,2 Also, view the mechanism of action video for Eleview®.

Go to Composition
Safety and tolerability of Eleview®

Safety

Learn how Eleview® is safe and well tolerated during GI resection procedures.1 Review the results of the clinical trial and see how Eleview® safety was found comparable to normal saline with methylene blue.2,3

Go to Safety

INDICATIONS FOR USE

Eleview® submucosal injectable composition is intended for use in gastrointestinal endoscopic procedures for submucosal lift of polyps, adenomas, early-stage cancers, or other gastrointestinal mucosal lesions, prior to excision with a snare or endoscopic device.

CONTRAINDICATIONS

Patients with known sensitivity to any of the components contained in Eleview®.

WARNINGS AND PRECAUTIONS

  • The endoscopist injecting Eleview® must be experienced in the administration technique.
  • The safety of Eleview® has not been established in pregnant or lactating women, or in children under 18 years of age.
  • Eleview® is provided in single-use ampoules. Eleview® should not be reused after the first opening. Any emulsion not injected during the procedure should not be reused for another endoscopic procedure.
  • Do not use if the primary packaging (ampoule) or secondary packaging (aluminum pouch) is damaged.
  • Do not use if the twist-off cap is damaged.
  • Do not use if the emulsion is not clear, shows any signs of opalescence, or contains floating or precipitated visible particles.
  • The product compatibility with other substances has not been tested.

ADVERSE REACTIONS

Rarely, local bleeding and/or inflammatory reaction could occur which may or may not be associated with Eleview®.

DOSAGE AND ADMINISTRATION

The administered dose of Eleview® should be determined based on the dimensions of the lesion to be removed. Inject into the submucosa the amount of Eleview® needed to form a submucosal cushion of optimal height and shape for the lesion to be removed. During the procedure do not exceed a total dose of 50 mL per patient, either in single or in multiple administrations.

Please see Instructions for Use for complete Important Safety Information.